Varicella vaccine meningoencephalitis in a child receiving autologous bone marrow transplantation
Pediatric Transplantation · 2023
DOI: 10.1111/petr.14562 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Transplantation, 2023. Verfasst von Raad Coralie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, Department of Pediatrics, CHU Sainte-Justine, Université de Montréal (QC), Montréal, Canada. Hauptthemen laut MEDLINE: Chickenpox, Herpes Zoster, Meningoencephalitis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Varicella vaccine, a live‐attenuated Oka‐strain of varicella zoster virus (VZV), is a recommended childhood vaccine by many countries. As with wild varicella strain, after primary infection, the live‐attenuated virus can establish latency in sensory ganglia and reactivate causing vaccine‐strain illnesses: herpes zoster (HZ), visceral or peripheral and central nervous system dissemination. We report a case of early reactivation of live‐attenuated virus—HZ and meningoencephalitis—in an immunocompromised child.
Methods
This is a retrospective descriptive report of a case, in a tertiary pediatric hospital, CHU Sainte‐Justine (Montréal, Canada).
Results
An 18 month‐year old girl diagnosed with a primitive neuro‐ectodermal tumor (PNET) received the day prior to diagnosis, a first varicella vaccine (MMRV). She received chemotherapy 20 days post MMRV vaccine and autologous bone marrow transplantation 3 months post vaccination. She was considered not eligible, to acyclovir prophylaxis prior transplantation (positive for VZV IgG and negative for herpes simplex virus IgG by ELISA). At day 1 post transplantation, she developed dermatomal HZ and meningoencephalitis. Oka‐strain varicella was isolated, she was treated with acyclovir and foscarnet. Neurologic status improved in 5 days. Control of VZV viral load in cerebrospinal fluid showed a slow decrease to from 5.24 log 10 copies/mL to 2.14 log 10 copies/mL in 6 weeks. No relapse was observed. She recovered without neurological sequelae.
Conclusions
Our experience highlights the importance of conducting a thorough medical history regarding vaccination and serological status of newly immunocompromised patients. Intensive chemotherapy succeeding live vaccine administration
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Division, Department of Pediatrics, CHU Sainte-Justine, Université de Montréal (QC), Montréal, Canada.
- Microbiology Division, CHU Sainte-Justine, Université de Montréal (QC), Montréal, Canada.
- Hematology and Oncology Division, Department of Pediatrics, CHU Sainte-Justine, Université de Montréal (QC), Montréal, Canada.
- Infectious Diseases Division, Department of Pediatrics, CHUQ-Université Laval, Québec, Canada.
ORCID-Profile: Raad Coralie
Zitieren
APA
Coralie, R., Ziad, C., Christian, R., Pierre, T., Chantal, B., Bruce, T., & Philippe, O. (2023). Varicella vaccine meningoencephalitis in a child receiving autologous bone marrow transplantation. Pediatric Transplantation. https://doi.org/10.1111/petr.14562
Vancouver
Coralie R, Ziad C, Christian R, Pierre T, Chantal B, Bruce T, et al. Varicella vaccine meningoencephalitis in a child receiving autologous bone marrow transplantation. Pediatric Transplantation. 2023. doi:10.1111/petr.14562
BibTeX
@article{Coralie2023,
author = {Coralie, Raad and Ziad, Chebel and Christian, Renaud and Pierre, Teira and Chantal, Buteau and Bruce, Tapiéro and Philippe, Ovetchkine},
title = {Varicella vaccine meningoencephalitis in a child receiving autologous bone marrow transplantation},
journal = {Pediatric Transplantation},
year = {2023},
doi = {10.1111/petr.14562}
}
EUVIMED